List of investigational social anxiety disorder drugs

This is a list of investigational social anxiety disorder drugs, or drugs that are currently under development for clinical use in the treatment of social anxiety disorder (SAD; or social phobia) but are not yet approved.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

This list was last comprehensively updated in August 2024. It is likely to become outdated with time.

Under development

Phase 3

• Fasedienol (Aloradine; AM-005; PH-94B; 4-androstadienol) – vomeropherine
• Soclenicant (BNC-210; IW-2143) – α₇-nicotinic acetylcholine receptor negative allosteric modulator

Phase 2/3

• Riluzole sublingual (BHV-0223; Nurtec) – complex mechanism of action or glutamatergic modulator

Phase 2

• Cannabidiol (CBD; ATL5; RLS103) – cannabinoid receptor modulator and other actions
• FKW00GA (FKW-00GA; TGW-00AA; TGW00AA) – serotonin 5-HT_1A receptor partial agonist and serotonin 5-HT_2A receptor antagonist
• JNJ-42165279 (JNJ-5279) – fatty acid amide hydrolase (FAAH) inhibitor
• ONO-1110 – endocannabinoid synthesis regulator and indirect cannabinoid receptor modulator https://adisinsight.springer.com/drugs/800072581 https://synapse.patsnap.com/drug/4a1d21a5511d57cc2a2c1e7a98310f74 https://pryzm.ozmosi.com/product/29482
• Oxytocin (intranasal potentiated oxytocin; TI-001; TI-114; TNX-1900; TNX-2900) – oxytocin receptor agonist
• Vilazodone (Viibryd) – serotonin 5-HT_1A receptor partial agonist and serotonin reuptake inhibitor

Phase 1

• (R)-Midomafetamine ((R)-MDMA; R-MDMA; EMP-01) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT_2A, 5-HT_2B, 5-HT_2C receptor agonist, entactogen, and weak psychedelic hallucinogen
• SNTX-2643 (SENS-01) – atypical serotonin reuptake inhibitor (SRI) (kanna-derived)

Preclinical

• Dimethyltryptamine (DMT; N,N-Dimethyltryptamine; N,N-DMT) – non-selective serotonin receptor agonist and psychedelic hallucinogen
• PSYLO-3001 (Psylo-3001) – non-selective serotonin receptor agonist and psychedelic hallucinogen

Phase unknown

• Fluvoxamine extended-release – selective serotonin reuptake inhibitor
• Venlafaxine controlled-release – serotonin–norepinephrine reuptake inhibitor

Not under development

No development reported

• Bupropion (Wellbutrin) – norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator
• EX-597 (KDS-4103; ORG-231295; URB-597) – fatty acid amide hydrolase (FAAH) inhibitor`
• Guanfacine extended-release (Connexyn; Intuniv; Intuniv XR; S-877503; SHP 503; SPD-503) – α₂-adrenergic receptor agonist

Development discontinued

• AV-608 (CGP-60829; NK-608; NKP-608C; NKP608) – neurokinin NK₁ receptor antagonist
• Tradipitant (LY-686017; VLY-686) – neurokinin NK₁ receptor antagonist
• Verucerfont (GSK-561679; NBI-77860) – corticotropin-releasing hormone receptor 1 (CRF₁) antagonist

Formal development never or not yet started

• Small-molecule oxytocin receptor agonists (e.g., LIT-001)

Clinically used drugs

Approved drugs

Selective serotonin reuptake inhibitors

• Escitalopram (Lexapro; Cipralex) – selective serotonin reuptake inhibitor
• Fluvoxamine (Depromel; Luvox) – selective serotonin reuptake inhibitor
• Paroxetine (Dropax; Serestill; Paxil; Seroxat) – selective serotonin reuptake inhibitor
• Sertraline (Zoloft; Lustral) – selective serotonin reuptake inhibitor

Serotonin–norepinephrine reuptake inhibitors

• Venlafaxine (Dobupal; Effexor; Effexor XR; Elafax) – serotonin–norepinephrine reuptake inhibitor

Monoamine oxidase inhibitors

• Moclobemide (Manerix) – reversible inhibitor of monoamine oxidase A

Off-label drugs

• Alcohol (over-the-counter self-medication) – GABA_A receptor positive allosteric modulator
• Atypical antipsychotics (e.g., olanzapine, quetiapine) – monoamine receptor modulators
• Benzodiazepines (e.g., alprazolam, chlordiazepoxide, clonazepam, diazepam, lorazepam, oxazepam) – GABA_A receptor positive allosteric modulators
• Beta blockers (e.g., atenolol, propranolol) – β-adrenergic receptor antagonists
• Bupropion (Wellbutrin) – norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator
• Cannabidiol (CBD) – cannabinoid receptor modulator and other actions, found in cannabis
• Gabapentinoids (e.g., gabapentin, pregabalin) – α₂δ subunit-containing voltage-dependent calcium channel blockers
• Monoamine oxidase inhibitors (e.g., phenelzine, selegiline, tranylcypromine)
• NMDA receptor antagonists (e.g., ketamine)
• Other anticonvulsants (besides gabapentinoids) (e.g., topiramate, valproic acid, tiagabine)
• Psychostimulants (e.g., amphetamine, methylphenidate)
• Selective serotonin reuptake inhibitors (non-licensed) (e.g., citalopram, fluoxetine)
• Serotonin–norepinephrine reuptake inhibitors (non-licensed) (e.g., desvenlafaxine, duloxetine)
• Serotonin 5-HT_1A receptor agonists (e.g., buspirone)
• Tricyclic antidepressants (e.g., clomipramine, imipramine)

See also

• List of investigational drugs
• List of investigational generalized anxiety disorder drugs
• List of investigational panic disorder drugs
• List of investigational post-traumatic stress disorder drugs
• List of investigational anxiety disorder drugs
• List of investigational autism and pervasive developmental disorder drugs
• List of investigational aggression drugs

References

Further reading

External links

• AdisInsight - Springer